118 related articles for article (PubMed ID: 36397681)
1. Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies.
Abdel Alem S; El Garhy N; El Khateeb E; Khalil M; Cordie A; Elsharkawy A; Fouad R; Esmat G; Abdelbary MS
Trans R Soc Trop Med Hyg; 2023 Apr; 117(4):285-296. PubMed ID: 36397681
[TBL] [Abstract][Full Text] [Related]
2. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy.
Liu CH; Sun HY; Hsieh SM; Liu WC; Sheng WH; Liu CJ; Su TH; Tseng TC; Chen PJ; Hung CC; Kao JH
J Viral Hepat; 2021 Jun; 28(6):887-896. PubMed ID: 33759290
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
Michal JL; Rab S; Patel M; Kyle AW; Miller LS; Easley KA; Kalapila AG
AIDS Res Hum Retroviruses; 2018 Aug; 34(8):690-698. PubMed ID: 29766745
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
[TBL] [Abstract][Full Text] [Related]
5. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
[TBL] [Abstract][Full Text] [Related]
6. Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals: A multicenter retrospective study.
Tsai CY; Chen GJ; Tsai CS; Liou BH; Yang CJ; Tsai HC; Lin CY; Huang SH; Lin KY; Wang NC; Chen TC; Lee CH; Hung CC;
J Microbiol Immunol Infect; 2023 Aug; 56(4):718-728. PubMed ID: 37045634
[TBL] [Abstract][Full Text] [Related]
7. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection.
Liu CH; Sun HY; Liu CJ; Sheng WH; Hsieh SM; Lo YC; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
Aliment Pharmacol Ther; 2018 Jun; 47(12):1690-1698. PubMed ID: 29665069
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
[TBL] [Abstract][Full Text] [Related]
9. Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.
Soeiro CASP; Gonçalves CAM; Marques MSC; Méndez MJV; Tavares APRA; Horta AMLMFCA; Sarmento-Castro RMDR
BMC Infect Dis; 2018 Aug; 18(1):364. PubMed ID: 30075765
[TBL] [Abstract][Full Text] [Related]
10. HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Huhn GD; Ramgopal M; Jain MK; Hinestrosa F; Asmuth DM; Slim J; Goldstein D; Applin S; Ryu JH; Jiang S; Cox S; Das M; Nguyen-Cleary T; Piontkowsky D; Guyer B; Rossaro L; Haubrich RH
PLoS One; 2020; 15(1):e0224875. PubMed ID: 31995556
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
De A; Charak S; Bhagat N; Rathi S; Verma N; Premkumar M; Taneja S; Sharma A; Goel K; Singh V; Duseja A
J Viral Hepat; 2023 Sep; 30(9):740-745. PubMed ID: 37260083
[TBL] [Abstract][Full Text] [Related]
12. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Cordie A; Elsharkawy A; Abdel Alem S; Meshaal S; El Akel W; Abdellatif Z; Kamal W; Al Askalany M; Kamel S; Abdel Aziz H; Kandeel A; Esmat G
Trans R Soc Trop Med Hyg; 2020 Apr; 114(4):232-240. PubMed ID: 31925434
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis.
Li G; Zang K; Zhang G; Zhu D; Deng X
Virol J; 2018 Jan; 15(1):19. PubMed ID: 29351766
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.
Shin HP; Park JA; Burman B; Kozarek RA; Siddique A
Clin Mol Hepatol; 2017 Dec; 23(4):316-322. PubMed ID: 28827512
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
[TBL] [Abstract][Full Text] [Related]
17. Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study.
Liou BH; Sun HY; Yang CJ; Syue LS; Lee YL; Tang HJ; Tsai HC; Lin CY; Chen TC; Lee CY; Huang SH; Liu CW; Lu PL; Lin SP; Wang NC; Cheng A; Ko WC; Cheng SH; Hung CC;
Infect Dis Ther; 2021 Jun; 10(2):827-838. PubMed ID: 33733316
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Sulkowski MS; Naggie S; Lalezari J; Fessel WJ; Mounzer K; Shuhart M; Luetkemeyer AF; Asmuth D; Gaggar A; Ni L; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Rodriguez-Torres M; Dieterich D;
JAMA; 2014 Jul 23-30; 312(4):353-61. PubMed ID: 25038354
[TBL] [Abstract][Full Text] [Related]
19. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]